TrialSignal
Clinical trial intelligence report
A Pilot Study of Low-Dose Daunorubicin in Patients With Relapsed/Refractory Acute Leukemia
Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.
Generated
Jul 28, 2026
Report code
NCT02914977-Jul 28, 2026
NCT ID
NCT02914977
Status
COMPLETED
Phase
PHASE1
Sponsor
Tara Lin
Executive brief
Investment-Ready Snapshot
A Pilot Study of Low-Dose Daunorubicin in Patients With Relapsed/Refractory Acute Leukemia is a PHASE1 clinical asset sponsored by Tara Lin in Acute Lymphocytic Leukemia, Acute Myeloid Leukemia. SEO and diligence focus: Daunorubicin, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.
Source & freshness
Provenance
https://clinicaltrials.gov/study/NCT02914977
Indication
Acute Lymphocytic Leukemia
Modality
small molecule
Target
Daunorubicin
Intervention
Daunorubicin
Source record
Protocol Description
Detailed source ingestion pending.
Source record
Outcome Measures
Detailed source ingestion pending.
Source record
Eligibility
Detailed source ingestion pending.
AI analysis
Known Results And Readout Context
Detailed source ingestion pending.
IP intelligence
Patent And IP Landscape
Detailed source ingestion pending.
Source record
Contacts
Detailed source ingestion pending.